Trial Profile
A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD in Subjects With Alcohol-Induced Liver Decompensation (AILD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Extracorporeal hepatocyte-based therapy (Primary) ; Cell replacements
- Indications Alcoholic hepatitis; Alcoholic liver disorders; Liver failure
- Focus Registrational; Therapeutic Use
- Sponsors Vital Therapies
- 05 Jun 2018 New Zealand and Germany were planned locations.
- 05 Jun 2018 Results of a biomarker analysis presented at the Digestive Disease Week 2018
- 05 Jun 2018 Results analysing inflammation biomarkers during Elad treatment from studies VTI-208 and VTL-308 presented at the Digestive Disease Week 2018.